NORTHAMPTON, MA / ACCESSWIRE / October 10, 2024 / Viatris is continuously looking for ways to reduce the volume and types of ...

在其他近期新闻中，Viatris Inc.在财务和运营表现方面取得了重大进展。公司最近报告了强劲的2024年第二季度业绩，总收入达到38亿美元，运营收入增长2%。调整后的息税折旧及摊销前利润（EBITDA）上升至12亿美元，调整后每股收益（EPS）报告为0.69美元。这些积极结果使Viatris将2024年新产品收入预测提高到5亿至6亿美元之间。

We recently made a list of 10 Best NASDAQ Stocks Under $20 to Buy. In this piece, we will look at where Viatris Inc.

Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...

诺和诺德与Viatris旗下迈兰制药在一份联合文件中表示，已同意解决与诺和诺德减肥药Ozempic和Wegovy相关的专利纠纷。此前诺和诺德已分别在法院起诉Viatris和其他公司侵犯专利，以阻止拟议的仿制药。诺和诺德发言人当地时间10月7日证实了和解协议。

Viatris (VTRS) reported positive top-line results of Phase 3 study in Japan evaluating the safety and efficacy of EFFEXOR in adults ...

We recently compiled a list of 10 Best Stocks Under $15 To Buy Now. In this article, we will look at where Viatris Inc.

Novo Nordisk (NVO) and Viatris (NASDAQ:VTRS) have reportedly reached an agreement in their dispute over U.S. patents ...

Alongside the settlement, Novo and Viatris have asked the U.S. Patent and Trademark Office to terminate its review of the ...

根据美国专利局专利审判和上诉委员会周三做出的决定，在美国针对诺和诺德的专利案将被允许继续审理。 仿制药生产商 Viatris 对诺和诺德的 GLP-1 分子 Semaglutide 的三项专利提出了质疑，因为该公司认为这些专利实际上是基于糖尿病药物利拉鲁肽的，因此应予以撤销。 本周早些时候，仲裁庭拒绝对其中两项挑战进行“当事人审查”，但周三决定继续审理第三项挑战的案件。 “当事人复审”是美国专利制 ...

Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to Forbes' list of World's Best Employers 2024.

Viatris Announces Positive Top-line Results from Phase 3 Study of EFFEXOR® in Japanese Adults with Generalized Anxiety ...